The trial evaluates the effect of corneal crosslinking as pre-treatment before corneal transplantation. The goal is to improve graft survival by reducing pathological vessels through pre-treatment.
Written informed consent by subject and/or witness prior to any study-related procedures
Adult male and female subjects ≥ 18 years old
≥ 2 corneal quadrants covered by pathological corneal neovascularization
Absence of other clinical contraindications to any part or product of the treatment plan
< 2 corneal quadrants covered by pathological neovascularization
Corneal stromal thickness below 400 μm (except in the central 8 mm zone which will be replaced later by a new corneal transplant with new endothelium); peripheral stromal thinning below 400 μm in weakened recipient areas is acceptable for CXL if not affecting more than 50% of the corneal circumference (allowing for later endothelial repopulation)
Active or suspected intraocular inflammation
Active corneal ulceration
Claus Cursiefen
Lead sponsor
University of Cologne
Sponsor institution
Uniklinik Köln, Zentrum für Klinische Studien
Collaborator
Uniklinik Köln, Institut für Medizinische Statistik und Bioinformatik
Collaborator
German Federal Ministry of Education and Research
Collaborator